Active Biotech AB

As of March 31, 2026, Active Biotech AB carries a market capitalization of 144.72M, placing it among publicly traded companies globally. Its enterprise value stands at 91.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Active Biotech AB's next confirmed earnings release is scheduled for November 5, 2026.

As of March 31, 2026, Active Biotech AB has 26.36M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Active Biotech AB maintains a current ratio of 5.14, meaning it holds 5.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2026, Active Biotech AB posted a negative return on equity (ROE) of -100.73, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -75.93, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Active Biotech AB's stock has declined approximately 46.45% over the past 52 weeks. The 50-day moving average sits at 4.30, while the 200-day moving average is 8.38.

Over the twelve months ended March 31, 2026, Active Biotech AB generated - - in revenue and converted that into -34.70M in net income, yielding earnings per share of -1.95. EBITDA reached -35.00M, while operating income came in at -35.00M.

These figures are as of March 31, 2026. Total book value stands at 47.20M, with working capital of 45.10M providing operational flexibility.

Active Biotech AB produced -31.30M in operating cash flow over the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -32.05: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -40.42, meaning Active Biotech AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Active Biotech AB's most recent stock split took place on June 3, 2026 with a 100:1 split ratio.